N-Heterocyclic derivatives of the formula (I):
are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.
[EN] 3-DIARYLMETHYLENES AND USES THEREOF<br/>[FR] 3-DIARYLMÉTHYLÈNES ET LEURS UTILISATIONS
申请人:ATUX ISKAY LLC
公开号:WO2021188949A1
公开(公告)日:2021-09-23
3-Diarylmethylenes are disclosed. The compounds activate PP2A, suppress oncogenic kinase signaling, and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
N-Heterocyclic derivatives of formula (I) are described herein, as well as other N-Heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.